Zosano Pharma (Zosano Pharma) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Mar. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Zosano Pharma Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Zosano Pharma's net issuance of preferred for the three months ended in Mar. 2022 was $0.00 Mil. The number is 0, which means that Zosano Pharma has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Zosano Pharma's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2022 was $0.00 Mil.

Zosano Pharma Net Issuance of Preferred Stock Historical Data

The historical data trend for Zosano Pharma's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zosano Pharma Net Issuance of Preferred Stock Chart

Zosano Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Zosano Pharma Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Zosano Pharma Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Zosano Pharma Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Zosano Pharma's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Zosano Pharma (Zosano Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zosano Pharma Corp (OTCPK:ZSANQ) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

34790 Ardentech Court, Fremont, CA, USA, 94555

Website

https://www.zosanopharma.com

Zosano Pharma Corp is a clinical-stage biopharmaceutical company. It is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using the proprietary transdermal microneedle system. The system is designed to facilitate rapid drug absorption into the bloodstream, which can result in an improved pharmacokinetic profile compared to original dosage forms. The company's operating segment is to develop human pharmaceutical products. Its primary product candidate is Qtrypta (M207) which is the proprietary formulation of zolmitriptan delivered utilizing the system.

Executives

Christine Matthews	officer: Chief Financial Officer	C/O ZOSANO PHAMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555
Steven Lo	director, officer: Chief Executive Officer	C/O CORCEPT THERAPEUTICS, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94010
Donald J Kellerman	officer: VP, Clinical Dev & Med Affairs	INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466
Elaine Yang	director	C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555
Kenneth Greathouse	director	3260 WHIPPIE ROAD, UNION CITY CA 94587
Hayley Lewis	officer: See Remarks	C/O CARBYLAN THERAPEUTICS, INC., 3181 PORTER DRIVE, PALO ALTO CA 94304
Kathy M. Mcgee	director	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Linda S Grais	director	86 ALEJANDRA AVE, ATHERTON CA 94027
Joseph P Hagan	director	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Kleanthis G Xanthopoulos	director	9050 CAMINO SANTA FE, SAN DIEGO CA 92121
John Peter Walker	director	126 ISABELLA AVE, ATHERTON CA 94027
Aisling Capital Partners Iv, Lp	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Aisling Capital Partners Iv Llc	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Aisling Capital Iv, Lp	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Andrew N Schiff	10 percent owner	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022